Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer

[1]  David C. Smith,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[2]  P. Nelson,et al.  Integrative molecular profiling of routine clinical prostate cancer specimens. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  F. Saad,et al.  Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). , 2015 .

[4]  C. Sander,et al.  Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling , 2014, Molecular Cancer Therapeutics.

[5]  P. Nelson.  Targeting the androgen receptor in prostate cancer--a resilient foe. , 2014, The New England journal of medicine.

[6]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[7]  Tiancheng Liu,et al.  From AR to c-Met: Androgen deprivation leads to a signaling pathway switch in prostate cancer cells , 2013, International journal of oncology.

[8]  S. Taneja,et al.  Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The Journal of urology.

[9]  David C. Smith,et al.  Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Ferraldeschi,et al.  Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer. , 2013, Annual review of medicine.

[11]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[12]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[13]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[14]  H. Scher,et al.  ARN-509: a novel antiandrogen for prostate cancer treatment. , 2012, Cancer research.

[15]  Jun Liu,et al.  Cooperation between Polycomb and androgen receptor during oncogenic transformation. , 2012, Genome research.

[16]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[17]  Jun Liu,et al.  Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors , 2011, Clinical Cancer Research.

[18]  J. Schalken,et al.  Steroidogenic Enzymes and Stem Cell Markers Are Upregulated during Androgen Deprivation in Prostate Cancer , 2011, Molecular medicine.

[19]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[20]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[21]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[22]  C. Roehrborn,et al.  Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer , 2008, Clinical Cancer Research.

[23]  Ganesh Venkatraman,et al.  Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. , 2008, Cancer letters.

[24]  T. Barrette,et al.  Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. , 2007, Neoplasia.

[25]  Yuzhuo Wang,et al.  The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. , 2007, Cancer research.

[26]  A. Joly.  104 POSTER Simultaneous blockade of VEGF and HGF receptors results in potent anti-angiogenic and anti-tumor effects , 2006 .

[27]  K. Nakashiro,et al.  Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells. , 2006, Biochemical and biophysical research communications.

[28]  B. Vandenbunder,et al.  Sequential activation of ERK and repression of JNK by scatter factor/hepatocyte growth factor in madin-darby canine kidney epithelial cells. , 2000, Molecular biology of the cell.

[29]  K. Matsumoto,et al.  Regulation of lnvasive Potential of Human Prostate Cancer Cell Lines by Hepatocyte Growth Factor , 1998, International journal of urology : official journal of the Japanese Urological Association.

[30]  P. Humphrey,et al.  Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. , 1995, The American journal of pathology.

[31]  P. Troncoso,et al.  Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. , 2015, European urology.

[32]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[33]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.